Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) - Pipeline Review, H2 2018

Global Markets Direct’s, ‘Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) - Pipeline Review, H2 2018’, provides in depth analysis on Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Oncology, Ophthalmology, Metabolic Disorders, Musculoskeletal Disorders, Dermatology, Gastrointestinal, Respiratory, Infectious Disease, Cardiovascular and Immunology under development targeting Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

  • Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV)

- The report reviews Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) targeted therapeutics and enlists all their major and minor projects

- The report assesses Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV)Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Biogen Inc

BioMAS Ltd

BrightGene Bio-Medical Technology Co Ltd

Factor Therapeutics Ltd

MedImmune LLC

Merck & Co Inc

Merck KGaA

Morphic Therapeutic Inc

Pliant Therapeutics ...

Biogen Inc

BioMAS Ltd

BrightGene Bio-Medical Technology Co Ltd

Factor Therapeutics Ltd

MedImmune LLC

Merck & Co Inc

Merck KGaA

Morphic Therapeutic Inc

Pliant Therapeutics Inc

SciFluor Life Sciences LLC

Tasly Pharmaceutical Group Co Ltd

Vascular Pharmaceuticals Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ...

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) - Overview

Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) - Companies Involved in Therapeutics Development

Biogen Inc

BioMAS Ltd

BrightGene Bio-Medical Technology Co Ltd

Factor Therapeutics Ltd

MedImmune LLC

Merck & Co Inc

Merck KGaA

Morphic Therapeutic Inc

Pliant Therapeutics Inc

SciFluor Life Sciences LLC

Tasly Pharmaceutical Group Co Ltd

Vascular Pharmaceuticals Inc

Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) - Drug Profiles

264-RAD - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

abituzumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Antibodies to Integrin Inhibit Alpha V and Beta 6 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AS-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BAT-2094 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BG-00011 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BGC-0222 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

C-16Y - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cilengitide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CWHM-12 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Fusion Protein to Antagonize Integrin Alpha V Beta 3 and Integrin Alpha 5 Beta 1 for Rheumatoid Arthritis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MK-0429 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MSP-68 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NOD-201 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OCU-200 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peptides to Antagonize Alpha-V Beta-3 Integrin Receptor for Metastatic Melanoma - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PLN-74809 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Proagio - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Protein to Agonize Integrin Alpha V, Beta 3 and Beta 5 for Malabsorption Syndrome - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein to Antagonize VEGFR2, ITGB3 and ITGAV for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RSF-201 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SF-0166 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize ITGAV and ITGB1 for Fibrosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize ITGAV and ITGB6 for Fibrosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize Integrin Alpha V for Fibrosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize Integrin Alpha V for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tetraiodothyroacetic acid - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VF-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VF-003 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VF-004 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VPI-2690B - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) - Dormant Products

Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) - Discontinued Products

Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) - Product Development Milestones

Featured News & Press Releases

Oct 09, 2018: Merck KGaA to announce data of Abituzumab at ESMO 2018 Congress

Oct 04, 2018: Factor Therapeutics announce treatment completion marks milestone in Phase 2 clinical trial

Oct 02, 2018: Factor Therapeutics provides shareholder update Q3 2018

Sep 05, 2018: Factor Therapeutics announced phase 2 clinical trial for venous leg ulcers nears completion

Aug 06, 2018: Pliant Therapeutics Receives FDA Orphan Drug Designation for Lead Program PLN-74809 in Idiopathic Pulmonary Fibrosis

Jul 19, 2018: Cassiopea announces top line positive proof of concept phase II results for CB-06-02 immune modulator in treating genital warts

Jul 16, 2018: Factor Therapeutics: Recruitment Completed in VF00102

Jun 26, 2018: VF00102 CLINICAL TRIAL UPDATE: Screening Closed to New Patients as Recruitment Nears Completion

Jun 14, 2018: Factor Therapeutics: VF001002 Clinical Trial Update

May 14, 2018: Factor Therapeutics announces its VF00102 Clinical Trial Recruitment Enters Final Phase

Apr 10, 2018: Factor Therapeutics Provides Update on VF00102 Clinical Trial

Dec 18, 2017: SciFluor announces positive top-line results of phase 1/2 study of SF0166 eye drops to treat wet age-related macular degeneration

Dec 12, 2017: SciFluor Announces 6 New Patent Issuances Covering the Use of SF0166 Topical Ophthalmic Solution in Retinal Diseases

Dec 07, 2017: Cassiopea Announces Completion of Recruitment of Phase II Proof of Concept Trial of CB-06-02 Trial in Genital Warts

Nov 29, 2017: Factor Therapeutics Announces 50% Recruitment Reached in VF00102 Clinical Trial

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number ...

List of Tables

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Indications, H2 2018

Number of Products under Development by Indications, H2 2018 (Contd..1), H2 2018

Number of Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Number of Products under Investigation by Universities/Institutes, H2 2018

Products under Investigation by Universities/Institutes, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Pipeline by Biogen Inc, H2 2018

Pipeline by BioMAS Ltd, H2 2018

Pipeline by BrightGene Bio-Medical Technology Co Ltd, H2 2018

Pipeline by Factor Therapeutics Ltd, H2 2018

Pipeline by MedImmune LLC, H2 2018

Pipeline by Merck & Co Inc, H2 2018

Pipeline by Merck KGaA, H2 2018

Pipeline by Morphic Therapeutic Inc, H2 2018

Pipeline by Pliant Therapeutics Inc, H2 2018

Pipeline by SciFluor Life Sciences LLC, H2 2018

Pipeline by Tasly Pharmaceutical Group Co Ltd, H2 2018

Pipeline by Vascular Pharmaceuticals Inc, H2 2018

Dormant Products, H2 2018

Dormant Products, H2 2018 (Contd..1), H2 2018

Dormant Products, H2 2018 (Contd..2), H2 2018

Dormant Products, H2 2018 (Contd..3), H2 2018

Discontinued Products, H2 2018

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number ...

List of Figures

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Top 10 Indications, H2 2018

Number of Products by Mechanism of Actions, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports